{"filing":{"accession_number":"0001104659-26-077556","cik":"0001390478","ticker":"SLS","company_name":"SELLAS Life Sciences Group, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"tm2618927d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926077556/tm2618927d1_8k.htm"},"events":[{"id":13751,"run_id":12214,"accession_number":"0001104659-26-077556","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses amendments to compensatory arrangements for three named executives: Dr. Angelos Stergiou (President and CEO), John Burns (Senior Vice President and CFO), and Dr. Dragan Cicic (Senior Vice President and Chief Development Officer). The amendments modify severance and change-of-control benefits, including lump-sum payments, extended severance periods (9-18 months), bonus provisions, COBRA reimbursement, and equity acceleration upon termination. These are classic executive compensation arrangements subject to Item 5.02(e) disclosure and would materially affect investor assessment of executive retention costs and change-of-control obligations.","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":10980,"accession_number":"0001104659-26-077556","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses amendments to compensatory arrangements for three named executives: Dr. Angelos Stergiou (President and CEO), John Burns (Senior Vice President and CFO), and Dr. Dragan Cicic (Senior Vice President and Chief Development Officer). The amendments modify severance and change-of-control benefits, including lump-sum payments, extended severance periods (9-18 months), bonus provisions, COBRA reimbursement, and equity acceleration upon termination. These are classic executive compensation arrangements subject to Item 5.02(e) disclosure and would materially affect investor assessment of executive retention costs and change-of-control obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:32:13.904673+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10980,"accession_number":"0001104659-26-077556","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses amendments to compensatory arrangements for three named executives: Dr. Angelos Stergiou (President and CEO), John Burns (Senior Vice President and CFO), and Dr. Dragan Cicic (Senior Vice President and Chief Development Officer). The amendments modify severance and change-of-control benefits, including lump-sum payments, extended severance periods (9-18 months), bonus provisions, COBRA reimbursement, and equity acceleration upon termination. These are classic executive compensation arrangements subject to Item 5.02(e) disclosure and would materially affect investor assessment of executive retention costs and change-of-control obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:32:13.904673+00:00","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-06-25"}]}